Business Context and Reporting Period
This Form 6-K filing is submitted by Hexindai Inc., a foreign private issuer, for the month of November 2018. The registrant's principal executive office is located in Beijing, People's Republic of China. The filing was signed by Zhang Qisen (Johnson), Chief Financial Officer, on November 16, 2018. The document serves as a report pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a cover sheet and exhibit index rather than a financial statement.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. No comparative financial data or operational updates are included in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document lists two exhibits: a letter from Marcum Bernstein & Pinchuk LLP to the SEC and a Press Release, but the content of these exhibits is not included in the input text.
Investor Verification Checklist
- Verify the content of Exhibit 99.1 (Press Release) to understand the specific event triggering this filing.
- Review the letter from Marcum Bernstein & Pinchuk LLP (Exhibit 16.1) for any auditor-related disclosures or resignations.
- Confirm the discrepancy between the requested company name "Akso Health Group" and the registrant name "Hexindai Inc." listed in the filing.
- Check subsequent filings for the actual financial data referenced in the press release.